Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
Transfus Apher Sci. 2021 Dec;60(6):103203. doi: 10.1016/j.transci.2021.103203. Epub 2021 Jul 1.
Congenital fibrinogen disorders (CFDs) are caused by mutations in the FGA, FGB and FGG genes and are classified as quantitative and qualitative fibrinogen defects. This study sought to determine the genetic background of CFDs in Iran and to examine the genotype-phenotype correlation.
Fourteen patients with a CFD diagnosis were included. Fibrinogen antigen and activity were measured by the immunoturbidimetric and Clauss methods respectively. Gene sequencing was performed following a polymerase chain reaction amplification of fibrinogen's genes. The ISTH Bleeding Assessment Tool was also evaluated for all cases.
Patients were diagnosed with dysfibrinogenemia (n = 10), hypodysfibrinogenemia (n = 2) and afibrinogenemia (n = 2). Seven different mutations located on FGA exon 2 (57 %), exon 4 (7%), exon 5 (7%) and FGG exon 8 (29 %) were identified. In patients with qualitative deficiencies, mutations were including p.Arg38Thr, p.Arg35His, p.Arg35Cys, p.Val145Asp, and p.Arg301Cys and were including p.Gly316GlufsX105 and p.Trp52stop in afibrinogenemic patients. In dysfibrinogenemia, two hotspot mutations, FGA Arg35 and FGG Arg301 were identified in 60 % of patients and the remaining (40 %) had p.Arg38Thr mutation. The p.Val145Asp and two hotspot mutations, p.Arg35His, p.Arg35Cys, were identified for the first time in Iran. The overall median (range) bleeding score (BS) was 4 (0-6) in all patients and it was 3.5 (0-5) in dysfibrinogenemia. Cutaneous bleeding and menorrhagia were the most common bleeding manifestations.
There was a weak genotype-phenotype correlation in CFDs and patients with dysfibrinogenemia were more symptomatic than in previous studies. Despite ethnic's differences, the prevalence of hotspot mutations in dysfibrinogenemia was similar to the other studies.
先天性纤维蛋白原异常症(CFD)是由 FGA、FGB 和 FGG 基因突变引起的,可分为纤维蛋白原定量和定性缺陷。本研究旨在确定伊朗 CFD 的遗传背景,并研究基因型-表型相关性。
纳入 14 例 CFD 患者。纤维蛋白原抗原和活性分别采用免疫比浊法和 Clauss 法测定。聚合酶链反应扩增纤维蛋白原基因后进行基因测序。还对所有病例进行了国际血栓与止血学会出血评估工具(ISTH Bleeding Assessment Tool)评估。
患者被诊断为异常纤维蛋白血症(n = 10)、低纤维蛋白血症(n = 2)和无纤维蛋白血症(n = 2)。在 FGA 外显子 2(57%)、外显子 4(7%)、外显子 5(7%)和 FGG 外显子 8(29%)上发现了 7 种不同的突变。在定性缺陷患者中,突变包括 p.Arg38Thr、p.Arg35His、p.Arg35Cys、p.Val145Asp 和 p.Arg301Cys,在无纤维蛋白血症患者中包括 p.Gly316GlufsX105 和 p.Trp52stop。在异常纤维蛋白血症中,60%的患者存在两个热点突变 FGA Arg35 和 FGG Arg301,其余(40%)患者存在 p.Arg38Thr 突变。p.Val145Asp 和两个热点突变 p.Arg35His、p.Arg35Cys 在伊朗是首次发现。所有患者的总中位数(范围)出血评分(BS)为 4(0-6),异常纤维蛋白血症患者为 3.5(0-5)。皮肤出血和月经过多是最常见的出血表现。
在 CFD 中存在较弱的基因型-表型相关性,异常纤维蛋白血症患者比以往研究更有症状。尽管存在种族差异,但异常纤维蛋白血症中热点突变的患病率与其他研究相似。